Emerging Infectious Diseases Pose Current and Future Challenges

AJMS Symposium Provides Update on Emerging Pathogens—Focusing on the South

Newswise — Newly recognized disease-causing viruses, bacteria, and other infections are continually emerging around the world, posing difficult challenges for patient diagnosis and treatment and for public health responses. A special symposium section of the September issue of The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation, provides a research update on important new infectious pathogens. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

Contributed by a distinguished panel of infectious disease experts, the papers in the symposium draw attention to emerging pathogens of various types and origins. The symposium emphasizes new infectious disease threats likely to be seen by doctors in the southern United States, while acknowledging the high impact of emerging pathogens in developing countries.

Many Emerging Pathogens, Many Contributing FactorsOf approximately 1,400 infectious pathogens recognized in 2005, about 180 met criteria for "emerging or re-emerging" pathogens, according to an introductory article by symposium editors Ronald A. Greenfield, M.D., and Michael S. Bronze, M.D. Many different factors contribute to their emergence, such as changes in land use, societal changes, population health, and hospital and medical procedures. The symposium includes a review of the essential role played by mathematical models in predicting the course of emerging diseases, and thus in anticipating the public health needs.

Most emerging infectious disease events are caused by "zoonotic" pathogens originating from animal sources—most commonly from wildlife. Many of these infections emerge in "hotspots" around the equator, such as tropical Africa, Latin America, and much of Asia. But new zoonotic pathogens are also emerging in the southern United States, where doctors are dealing with toxocariasis, a parasitic infection carried by pets; bovine tuberculosis, which can spread from cattle to humans; and some new tick-borne diseases. The H1N1 "swine flu" is a zoonotic infection, while the threat of a H5N1 "bird flu" pandemic remains.

In the United States, the emergence of antibiotic-resistant bacteria is a major problem, including "superbugs" like multi drug-resistant strep. Two symposium articles discuss efforts to develop safe and effective vaccines against these difficult-to-treat bacteria. While some drug-resistant bacteria are declining, others are becoming increasingly important causes of clinical infection.

The emergence of a "hypervirulent" strain of Clostridium difficile is a particularly difficult problem. Once found only in patients previously treated with antibiotics, C. difficile is now appearing in other groups as well. Infections with fungal pathogens such as Candida and Aspergillus—once seen mainly in patients with suppressed immune function—have now spread to other groups of patients.

Meanwhile, food- and water-borne infections continue to pose a major threat to human health. In developing countries, water sanitation techniques are cost-effective in controlling these pathogens. "In the United States, food safety could be dramatically improved by food irradiation," Drs. Greenfield and Bronze write.

Many other infectious pathogens could be added to the list—including HIV, which is still considered an emerging pathogen, along with multidrug-resistant and "extensively drug resistant" tuberculosis. Hepatitis B and C virus and malaria also continue to threaten large segments of the world population.

Even as new pathogens are emerging, so are technologies that may lead to effective new prevention and treatment strategies. Molecular biology techniques are being used to study how infectious pathogens interact with human hosts, while advanced genetic techniques are being used to enhance diagnosis and treatment. Molecular approaches to the development of new vaccines are progressing as well. The editors hope the symposium will promote increased awareness of emerging pathogens, and encourage progress toward advances in monitoring, diagnosis, and treatment.

About The American Journal of the Medical SciencesFounded in 1820, The American Journal of the Medical Sciences (AJMS) is the official journal of the Southern Society for Clinical Investigation. Regular features include Clinical and Basic Investigation studies, Reviews, Historical Articles, Case Reports, Images in the Medical Sciences. Other special features include contributions from the Southwestern Internal Medicine Conference, Cardiology Grand Rounds from Vanderbilt and Emory Universities, Case Records of the VA Maryland Healthcare System/University of Maryland Medicine, and Clinical Pathological Correlation from Texas A&M Health Science/Scott & White Memorial Hospital. The AJMS publishes original articles dealing with topics such as infectious disease, rheumatology/immunology, hematology/oncology, cardiology, pulmonology/critical care, gastroenterology, nephrology, neurology and endocrinology. Visit the journal website at www.amjmedsci.com.

About the Southern Society for Clinical InvestigationFounded in 1946, the Southern Society for Clinical Investigation (SSCI) is a regional academic society dedicated to the advancement of medically-related research. Its major focus is on encouraging students and postgraduate trainees (residents and fellows) to enter academic medicine and to support junior faculty success in clinical investigation. SSCI members are committed to mentoring future generations of medical investigators and promoting careers in academic medicine. Visit the SSCI website at www.ssciweb.org.

About Lippincott Williams & Wilkins Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services.

LWW is part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health and pharmacy. Major brands include traditional publishers of medical and drug reference tools and textbooks, such as Lippincott Williams & Wilkins and Facts & Comparisons®; and electronic information providers, such as Ovid®, UpToDate®, Medi-Span® and ProVation® Medical.

Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance, and healthcare rely on Wolters Kluwer’s leading, information-enabled tools and solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer has 2009 annual revenues of €3.4 billion ($4.8 billion), employs approximately 19,300 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Alphen aan den Rijn, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices